EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m.
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-stage study.
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral vaccine response rate at the dose selected for advancement, with comparable immuno...
Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and management is projecting significant sales and market share growth through 2030. Dynavax boasts a robust balance sheet, recently completed a $200M buyback, and is well-regarded by analysts, support...
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 million Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025 Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant program C...
EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.